sur Evotec AG (NASDAQ:EVTCY)
Evotec Announces Transition of Chief Scientific Officer
Evotec SE has announced a leadership transition as Chief Scientific Officer Dr. Cord Dohrmann is set to step down on September 30, 2026. Dr. Dohrmann, who has significantly contributed to Evotec’s scientific achievements over the last 16 years, will leave by mutual consent. The company is currently searching for his successor.
Evotec's CEO, Dr. Christian Wojczewski, praised Dr. Dohrmann for his role in enhancing the firm's scientific capabilities, particularly in areas like iPSC-based technologies. This scientific foundation is viewed as critical for Evotec’s ongoing growth.
Dr. Dohrmann expressed gratitude for the collaborations during his tenure and looks forward to witnessing the continued scientific advancements at Evotec.
This change marks a new chapter for Evotec, promising continued innovation in drug discovery and development.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Evotec AG